Clinical Trial Update: (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update on IMPRIME PGG with BTH1704 plus gemcitabine for advanced pancreatic cancer; the study NCT02132403 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• BTH1704
• Gemcitabine (Gemcitabine)
• Imprime PGG

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED